FOLLOWUS
1. Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
2. Chinese Clinical Basic Institute, China Academy of Chinese Medical Sciences,Beijing,China
3. Department of Pharmaceutics, Third Hospital Affiliated Peking University,Beijing,China
纸质出版日期:2012,
网络出版日期:2012-12-13,
Scan for full text
Wang, Jn., Jiang, Jj., Xie, Ym. et al. Population pharmacokinetics of naringin in total flavonoids of Drynaria Fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis., Chin. J. Integr. Med. 18, 925–933 (2012). https://doi.org/10.1007/s11655-012-1296-0
Jian-nong Wang, Jun-jie Jiang, Yan-ming Xie, et al. Population pharmacokinetics of naringin in total flavonoids of Drynaria Fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis[J]. Chinese Journal of Integrative Medicine, 2012,18(12):925-933.
Wang, Jn., Jiang, Jj., Xie, Ym. et al. Population pharmacokinetics of naringin in total flavonoids of Drynaria Fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis., Chin. J. Integr. Med. 18, 925–933 (2012). https://doi.org/10.1007/s11655-012-1296-0 DOI:
Jian-nong Wang, Jun-jie Jiang, Yan-ming Xie, et al. Population pharmacokinetics of naringin in total flavonoids of Drynaria Fortunei (Kunze) J. Sm. in Chinese women with primary osteoporosis[J]. Chinese Journal of Integrative Medicine, 2012,18(12):925-933. DOI: 10.1007/s11655-012-1296-0.
To evaluate the effect of covariates on the pharmacokinetic profiles of naringin in the total flavonoids of Drynaria fortunei (Kunze) J. Sm. in the Qianggu Capsule (强骨胶囊) by evaluating Chinese women with primary osteoporosis. A total of 98 female patients from the communities of Jingshan
Beixinqiao
Jiaodaokou
Chaoyangmen
and Donghuamen in Beijing
China
aged 40 to 80 years
were included in this study. Blood samples were collected before and 0.5
1
2
3
4
6
8
10
12
and 24 h after a single oral dose of Qianggu Capsule. The concentration in blood samples from 32 patients before and 0.5
1
2
3
and 4 h after drug administration were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method
and full set of pharmacokinetic data was analyzed with nonlinear mixed-effect modeling (NONMEM) software. The mean of population parameters clearance (C1)
central distribution volume (V)
absorption rate constant (Ka1)
inter-compartmental clearance (C2)
peripheral distribution volume (V2) were set as parameters and estimated through base model
covariate model
and final model. Age
height
weight
blood urea nitrogen (BUN)
serum creatinine (Scr)
alanine transaminase (ALT)
aspartate transaminase (AST)
hyperlipidemia
Liver (Gan) Kidney (Shen) yin insufficiency (GSYI)
Kidney (Shen) yang insufficiency (SYI) were set as covariates. The relationships between these parameters and covariates were analyzed. The results showed that C1 was the main parameter influenced by the selected covariates among the population parameters
and the relationships between the covariates and C1 were analyzed
among the selected covariates hyperlipidemia was identified as significant covariate of C1. The pharmacokinetic behaviors of naringin are altered with hyperlipidemia in Chinese women with primary osteoporosis.
To evaluate the effect of covariates on the pharmacokinetic profiles of naringin in the total flavonoids of Drynaria fortunei (Kunze) J. Sm. in the Qianggu Capsule (强骨胶囊) by evaluating Chinese women with primary osteoporosis. A total of 98 female patients from the communities of Jingshan
Beixinqiao
Jiaodaokou
Chaoyangmen
and Donghuamen in Beijing
China
aged 40 to 80 years
were included in this study. Blood samples were collected before and 0.5
1
2
3
4
6
8
10
12
and 24 h after a single oral dose of Qianggu Capsule. The concentration in blood samples from 32 patients before and 0.5
1
2
3
and 4 h after drug administration were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method
and full set of pharmacokinetic data was analyzed with nonlinear mixed-effect modeling (NONMEM) software. The mean of population parameters clearance (C1)
central distribution volume (V)
absorption rate constant (Ka1)
inter-compartmental clearance (C2)
peripheral distribution volume (V2) were set as parameters and estimated through base model
covariate model
and final model. Age
height
weight
blood urea nitrogen (BUN)
serum creatinine (Scr)
alanine transaminase (ALT)
aspartate transaminase (AST)
hyperlipidemia
Liver (Gan) Kidney (Shen) yin insufficiency (GSYI)
Kidney (Shen) yang insufficiency (SYI) were set as covariates. The relationships between these parameters and covariates were analyzed. The results showed that C1 was the main parameter influenced by the selected covariates among the population parameters
and the relationships between the covariates and C1 were analyzed
among the selected covariates hyperlipidemia was identified as significant covariate of C1. The pharmacokinetic behaviors of naringin are altered with hyperlipidemia in Chinese women with primary osteoporosis.
naringinpopulation pharmacokineticsQianggu Capsuletotal flavonoids of Drynaria fortunei
naringinpopulation pharmacokineticsQianggu Capsuletotal flavonoids of Drynaria fortunei
Pharmacopoeia Commission of People’s Republic of China (Chinese ed). Vol. I. Pharmacopoeia of the People’s Republic of China. Beijing: Chemical Industry Press; 2005:179–180.
Li XH, Xiong ZhL, Lu Sh, Zhang Y, Li FM. Pharmacokinetics of naringin and its metabolite naringenin in rats after oral administration of rhizoma Drynariae extract assayed by UPLC-MS/MS. Chin J Nat Med 2010;8:40–46.
Su L, Liu QD. Biological activity and pharmacokinetics of Naringin. Guangzhou Univ Chin Med (Chin) 2008;2:74–80.
China Association of Medicine, 1st ed. Guideline of clinical diagnosis: subvolume of osteoporosis and born minral salt diseases. Beijing: People’s health press; 2010:1–7.
Ishii K, Furuta T, Kasuya Y. Determination of naringin and naringenin in human plasma by high-performance liquid chromatography. J Chromatogr B 1996;683:225–229.
Ishii K, Furuta T, Kasuya Y. Determination of naringin and naringenin in human urine by high-performance liquid chromatography utilizing solid-phase extraction. J Chromatogr B 1997;704:299–305.
Fang T, Wang T, Ma Y, Su W, Bai Y, Zhao P. A. rapid LC/MS/MS quantitation assay for naringin and itstwo metabolites in rats plasma. J Pharm Biomed Anal 2006;40:454–459.
Food and Drug Adminstration. Guidance for Industry Population Pharmacokinetics 1999.
Sheiner LB, Rosenberg B, Marathe VV. Estimation of population Characteristics of pharmacokinetics parameters from routine clinical data. J Pharmacokinet Biopharm 1977;5:445–479.
0
浏览量
77
Downloads
5
CSCD
关联资源
相关文章
相关作者
相关机构